Histology
Large Cell Carcinoma
CI-CAN-00001061Explore in graph →
47 active trials2 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001061Explore in graph →
Clinical trials
159 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT01236547 |
| Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer |
| completed |
| Phase 2 |
| 123 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 19, 2022 |
| clinicaltrials |
| NCT02688608 | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 6 | Saad A KhanOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02726503 | Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer(HOPE) | completed | Phase 2 | 39 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | terminated | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00408694 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | terminated | Phase 2 | 53 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT00454142 | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01497041 | A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment | unknown | Phase 2 | 35 | Korean South West Oncology GroupNETWORK | 1 | Dec 22, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2023source: clinicaltrials